2024
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.Peer-Reviewed Original ResearchAbstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases
Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.Peer-Reviewed Original ResearchColorectal cancer peritoneal metastasesCRC PMPeritoneal metastasisColorectal cancerIntra-tumor heterogeneitySystemic regimensTherapeutic targetAmerican Association for Cancer Research annual meetingsPrognosis of peritoneal metastasisResistant to systemic chemotherapyPlasma-peritoneal barrierOncological surgical resectionColorectal cancer patientsSystemic chemotherapySurgical resectionPalliative surgerySystemic therapyAntineoplastic therapyPotential therapeutic targetExploratory laparotomyTranscoelomic metastasisPoor prognosisFFPE tissue samplesSynchronous PMPoor responseEfficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Shitara K, Falcone A, Fakih M, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. The Oncologist 2024, 29: e601-e615. PMID: 38366864, PMCID: PMC11067808, DOI: 10.1093/oncolo/oyae007.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerRefractory metastatic colorectal cancerAdverse eventsDiscontinuation rate due to adverse eventsColorectal cancerChemorefractory metastatic colorectal cancerSafety outcomesMedian overall survivalSafety of FTD/TPIProgression-free survivalAdvanced solid tumorsAssociated with improved outcomesEarly-phase studiesSystematic reviewOverall survivalFTD/TPIRetrospective studySolid tumorsBevacizumabClinical efficacyTargeted agentsTumor typesAntineoplastic agentsAdvanced cancerImprove outcomes
2023
593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.Peer-Reviewed Original ResearchValue-driven colorectal cancer survivorship through partnership with primary care.
Chan G, Ho C, Lin Z, Wu J, Chieng J, Lieske B, Yong W, Sundar R, Tan H, Ho J, Choo J, Walsh R, Cheong W, Tan K, Chee C, Liu X, Lim F, Goh S, Chee C. Value-driven colorectal cancer survivorship through partnership with primary care. Journal Of Clinical Oncology 2023, 41: 6649-6649. DOI: 10.1200/jco.2023.41.16_suppl.6649.Peer-Reviewed Original ResearchPrimary care providersSurvivorship careHealthcare resourcesPrimary careSpecialist visitsColorectal cancerStage distribution of cancersColorectal cancer survivorshipColorectal cancer survivorsSurvivorship care plansUtilization of healthcare resourcesCancer CenterFollow-up careDistribution of cancerNational University Cancer InstituteAcademic cancer centerCancer recurrenceCRC survivorsCancer survivorshipCare planningCare providersHealthcare utilizationPreventive healthHealthcare expendituresTertiary careMalignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer.
Gwee Y, Chia D, Provenzano L, Lonardi S, Conca V, Cremolini C, Yong W, Tan P, So J, Kim G, Shabbir A, Ong J, Pietrantonio F, Sundar R. Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer. Journal Of Clinical Oncology 2023, 41: 455-455. DOI: 10.1200/jco.2023.41.4_suppl.455.Peer-Reviewed Original ResearchPeritoneal cancer indexPresence of malignant ascitesPeritoneal metastasisMalignant ascitesColorectal cancer patientsGastric cancerColorectal cancerOverall survivalGastrointestinal malignanciesPoor survivalCohort of gastric cancerMedian peritoneal cancer indexPeritoneal cancer index scoreFirst-line systemic treatmentResistant to systemic therapyMetastatic gastrointestinal malignanciesMedian overall survivalStage IV diseaseMetastatic CRC patientsAbsence of ascitesClinico-pathological dataPoor survival outcomesTertiary oncology centerStudy of patientsRandomized clinical trials
2022
Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants
Teo Y, Tan B, Tan N, Yap D, Chai Y, Teo Y, Sia C, Sundar R, Tan E, See A, Toh S. Obstructive sleep apnea and the incidence and mortality of gastrointestinal cancers: a systematic review and meta-analysis of 5,120,837 participants. Journal Of Gastrointestinal Oncology 2022, 0: 0-0. PMID: 36636076, PMCID: PMC9830329, DOI: 10.21037/jgo-22-153.Peer-Reviewed Original ResearchObstructive sleep apneaAssociation of obstructive sleep apneaSleep apneaGastrointestinal cancerCancer incidenceColorectal cancerMeta-analysisPancreatic cancerFollow-upObstructive sleep apnea screeningYears of median follow-upColorectal cancer screening guidelinesLong-term follow-upIncreased risk of colorectal cancerIncreased incidence of colorectal cancerRisk of colorectal cancerIncidence of colorectal cancerMedian follow-upPancreatic cancer incidenceCancer screening guidelinesSleep apnea screeningIncidence of gastrointestinal cancerMortality of gastrointestinal cancersSystematic reviewHigh-risk individualsReal-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.Peer-Reviewed Original ResearchMetastatic colorectal cancerTAS-102Median PFSBiweekly dosesDiscontinued treatment due to toxicityColorectal cancerDose of TAS-102Treated with TAS-102Treatment due to toxicityMetastatic colorectal cancer patientsGrade 3 neutropeniaThird-line treatmentInitiation of treatmentRetrospective observational studyBiweekly regimenDose delaysFebrile neutropeniaHigher neutropeniaStandard regimenDose reductionBevacizumabGrade 3Adverse eventsDisease progressionNeutropenia
2020
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
Ng C, Jiang A, Toh E, Ng C, Ong Z, Peng S, Tham H, Sundar R, Chong C, Khoo C. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. International Journal Of Colorectal Disease 2020, 35: 1501-1512. PMID: 32592092, DOI: 10.1007/s00384-020-03676-x.Peer-Reviewed Original ResearchConceptsColorectal adenomasCancer incidenceImprove colorectal cancer outcomesNon-metformin usersColorectal cancerIncidence of colorectal adenomasMeta-analysisMetformin usersIncidence of colorectal cancerHazard ratioRisk ratioReducing colorectal adenomasColorectal cancer outcomesCRC-specific survivalCancer survival outcomesEffect of metformin useMetformin useSurvival outcomesAdvanced adenomasDiet-only treatmentDerSimonian and LairdCancer outcomesOverall survivalMethodsA database searchConclusionThis meta-analysisThe chemo-brain effect in colorectal cancer patients.
Lee M, Chong W, Tan H, Chan G, Ho J, Sundar R, Chee C, Nasrallah F, Koo E, Yong W. The chemo-brain effect in colorectal cancer patients. Journal Of Clinical Oncology 2020, 38: e24095-e24095. DOI: 10.1200/jco.2020.38.15_suppl.e24095.Peer-Reviewed Original ResearchRapid Visual Information ProcessingQuality of lifePaired associate learningCambridge Neuropsychological Test Automated BatteryQLQ-C30 scoresMonths post-chemotherapyColorectal cancerRisk of poor recoveryMemory scoresHADS depression scoreQuality of Life QuestionnaireEORTC QLQ-C30 scoresPocket Smell TestHADS depressionLong-term cognitive impairmentDepression scoresPre-chemotherapyVisual information processingCorrelate of cognitive declinePost-chemotherapyColorectal cancer patientsNeuropsychological assessmentAssociative learningCognitive disturbancesBlood biomarker studies
2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorColorectal NeoplasmsDNA RepairFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedOxaliplatinPrognosisRetrospective StudiesSurvival RateYoung AdultConceptsATM lossColorectal cancerAssociated with superior overall survivalDNA repair targeting agentsMetastatic colorectal cancer patientsAtaxia telangiectasiaIrinotecan-based therapySuperior overall survivalOxaliplatin-based therapyOxaliplatin-based chemotherapyTreatment of colorectal cancerATM protein expressionClinical outcome dataNuclear staining intensityColorectal cancer patientsDrug Development UnitColorectal cancer samplesOverall survivalMutation statusH-scoreTargeted agentsClinical outcomesDNA repair signalingTumor samplesCancer patients
2017
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Sundar R, Hong D, Kopetz S, Yap T. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery 2017, 7: 558-560. PMID: 28576843, PMCID: PMC5458523, DOI: 10.1158/2159-8290.cd-17-0087.Peer-Reviewed Original Research
2016
383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
Heong V, Koe P, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Ho J, Gopinathan A, Lee S, Goh B, Tan D. 383P RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Annals Of Oncology 2016, 27: vi122. DOI: 10.1093/annonc/mdw368.26.Peer-Reviewed Original Research
2015
The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer.
Soh I, Mogro M, Soo R, Pang A, Tan C, Chuah B, Zee Y, Wong A, Ow S, Sundar R, Lim J, Huang Y, Ling W, Yong W. The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2015, 33: 770-770. DOI: 10.1200/jco.2015.33.3_suppl.770.Peer-Reviewed Original ResearchTarget area-under-the-curveArea under the curveArea under the curve levelsAsian patientsDose adjustmentPK samplingPK sampling time pointsPK-guided dose adjustmentMedian area-under-the-curveGastrointestinal (GI) cancersRates of toxicityProportion of patientsHeterogeneous tumor typesSystemic plasma levelsBody surface areaCorrelation of response ratesG3/4 neutropeniaG3/4 toxicitiesTumor typesGI cancersPlasma levelsMFOLFOX6 regimenColorectal cancerGastric cancerPatients